{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:36:29Z","timestamp":1770435389473,"version":"3.49.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.clinthera.2012.03.003","type":"journal-article","created":{"date-parts":[[2012,4,14]],"date-time":"2012-04-14T08:17:12Z","timestamp":1334391432000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia"],"prefix":"10.1016","volume":"34","clinical-trial-number":[{"clinical-trial-number":"nct00151528","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00282997","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00346034","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lesley M.","family":"Arnold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Emir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Kevin","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhardt G.","family":"Zeiher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynne","family":"Pauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayle","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Petersel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.03.003_bib1","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0889-857X(01)00008-4","article-title":"Office management of fibromyalgia","volume":"28","author":"Goldenberg","year":"2002","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.clinthera.2012.03.003_bib2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1521-6942(03)00030-5","article-title":"Pharmacological therapies in fibromyalgia","volume":"17","author":"Rao","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/art.1780330203","article-title":"The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia: report of the Multicenter Criteria Committee","volume":"33","author":"Wolfe","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.03.003_bib4","first-page":"2270","article-title":"Fibromyalgia syndrome","volume":"32","author":"Mease","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1521-6942(03)00035-4","article-title":"Chronic widespread pain and fibromyalgia: what we know, and what we need to know","volume":"17","author":"Clauw","year":"2003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.4065\/74.4.385","article-title":"Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia","volume":"74","author":"Bennett","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2012.03.003_bib7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/art.1780371106","article-title":"Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome","volume":"37","author":"Russell","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.03.003_bib8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/art.1780350509","article-title":"Cerebrospinal fluid biogenic amine metabolites in fibromyalgia\/fibrositis syndrome and rheumatoid arthritis","volume":"35","author":"Russell","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.03.003_bib9","first-page":"846","article-title":"Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation","volume":"19","author":"Yunus","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.tips.2006.12.006","article-title":"Ca2+ channel \u03b12\u03b4 ligands: novel modulators of neurotransmission","volume":"28","author":"Dooley","year":"2007","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.clinthera.2012.03.003_bib11","first-page":"502","article-title":"A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib12","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jpain.2008.03.013","article-title":"A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia","volume":"9","author":"Arnold","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.clinthera.2012.03.003_bib13","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3899\/jrheum.110569","article-title":"An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia","volume":"38","author":"Pauer","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.03.003_bib14","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pain.2008.02.027","article-title":"Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin","volume":"136","author":"Crofford","year":"2008","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2012.03.003_bib15","first-page":"51","article-title":"Self-report scales and procedures for assessing pain in adults","volume":"Vol 135","author":"Jensen","year":"1992"},{"key":"10.1016\/j.clinthera.2012.03.003_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812001531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:48:51Z","timestamp":1758962931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812001531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0149291812001531"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Profile and Tolerability of Up to 1 Year of Pregabalin Treatment in 3 Open-Label Extension Studies in Patients With Fibromyalgia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier HS Journals, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}